Optimizing therapeutic antibody function: progress with Fc domain engineering.
Kaneko
Etsuji
E
Antibody Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan.
Niwa
Rinpei
R
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000502:physiology / Q000627:therapeutic use*; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000235:genetics* / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics; D015202:Protein Engineering / Q000592:standards / Q000639:trends*; D017433:Protein Structure, Secondary / Q000235:genetics; D011961:Receptors, Fc / Q000235:genetics* / Q000502:physiology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D015395:Histocompatibility Antigens Class I; D007141:Immunoglobulin Fc Fragments; D011961:Receptors, Fc; C100688:Fc receptor, neonatal